ReAlta Life Sciences
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Complement C1q / neutrophil effectors (myeloperoxidase, NETosis)Peptide | Chronic Obstructive Pulmonary Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
18 May 2026Topline resultRLS-0071 (pegtarazimod)Phase 2 AE-COPD proof-of-concept results presented at ATS 2026
ReAlta Life Sciences · Source ↗
Financial reports
No financial reports recorded.